FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins
Executive Summary
FDA's ability to meet its Prescription Drug User Fee Act deadlines for new product approvals may end up below the agency's earlier estimates, according to Office of New Drugs Director John Jenkins
You may also be interested in...
Sponsors Can Expect REMS Discussions As Early As Phase II, FDA Says
Though REMS requirements caused longer reviews in 2008, FDA Deputy Director Office of New Drugs Sandra Kweder said the agency expects "we will be doing this better and it will not affect PDUFA deadlines" going forward.
FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally
FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year
FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally
FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year